
Eyenovia Investor Relations Material
Latest events

Q3 2024
Eyenovia

Q4 2024
17 Jun, 2025

Q1 2025
18 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Eyenovia Inc
Access all reports
Eyenovia Inc operates as a commercial-stage ophthalmic technology company. Its primary focus is on the commercialization of Mydcombi, a proprietary ophthalmic spray for mydriasis (pupil dilation) composed of tropicamide and phenylephrine, and the development of the Optejet device. The Optejet is designed for use in drug-device therapeutic product candidates for conditions such as presbyopia and pediatric progressive myopia, as well as for out-licensing for additional indications. Eyenovia's approach aims to change ocular drug delivery by achieving clinical microdosing of next-generation formulations of established pharmaceutical agents through its high-precision targeted ocular delivery system, potentially offering an alternative to conventional eyedropper delivery methods. The company is headquartered in NYC and its shares are listed on the Nasdaq.
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
EYEN
Country
🇺🇸 United States